Skip to main content
Top
Gepubliceerd in: Verslaving 2/2012

01-06-2012 | Middelen

Cannabidiol: de nieuwe haarlemmerolie of een hype?

Auteurs: Dr. R. J. M. Niesink, Dr. M.W. van Laar

Gepubliceerd in: Verslaving | Uitgave 2/2012

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Extract

Er gaat geen week voorbij of ergens in de krant, op radio, televisie of internet is er wel iets te melden over cannabis. In Nederland de laatste tijd veel over (coffeeshop)beleid, en tussen al het politiek gekrakeel door af en toe nog wel eens iets inhoudelijks. Opvallend is de aandacht voor cannabidiol (CBD). De belangrijkste psychoactieve stof in cannabis is tetrahydrocannabinol (THC). Cannabidiol is een stof die wel in hasj voorkomt, maar niet in wiet. Aan CBD worden, met name de laatste jaren, allerlei positieve eigenschappen toegedicht. Is die aandacht terecht? Is CBD inderdaad de nieuwe haarlemmerolie, het wondermiddel dat sommige onderzoekers denken dat het is? Is cannabis waarin meer CBD zit minder schadelijk dan cannabis die geen CBD bevat? Hebben mensen die hasj roken waarin veel CBD voorkomt minder kans op psychosen of minder kans verslaafd te raken dan mensen die wiet roken? In deze bijdrage zetten we een aantal zaken op een rijtje. …
Voetnoten
1
Oorspronkelijk werd wiet aangeduid als marihuana.
 
Literatuur
go back to reference Barkus, E., & Murray, R.M. (2010). Substance use in adolescence and psychosis: clarifying the relationship.Annual Review of Clinical Psychology, 6,365–389.PubMedCrossRef Barkus, E., & Murray, R.M. (2010). Substance use in adolescence and psychosis: clarifying the relationship.Annual Review of Clinical Psychology, 6,365–389.PubMedCrossRef
go back to reference Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H., De Oliveira, D.C., De Martinis, B.S., Kapczinski, F., Quevedo, J., Roesler, R., Schroder, N., Nardi, A.E., Martin-Santos, R., Hallak, J.E., Zuardi, A.W., & Crippa, J.A. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatmentnaive social phobia patients.Neuropsychopharmacology, 36,1219–1226.PubMedCrossRef Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H., De Oliveira, D.C., De Martinis, B.S., Kapczinski, F., Quevedo, J., Roesler, R., Schroder, N., Nardi, A.E., Martin-Santos, R., Hallak, J.E., Zuardi, A.W., & Crippa, J.A. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatmentnaive social phobia patients.Neuropsychopharmacology, 36,1219–1226.PubMedCrossRef
go back to reference Bhattacharyya, S., Morrison, P.D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O’Carroll, C.M., Seal, M., Allen, P., Mehta, M.A., Stone, J.M., Tunstall, N., Giampietro, V., Kapur, S., Murray, R.M., Zuardi, A.W., Crippa, J.A., Atakan, Z., & McGuire, P.K. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.Neuropsychopharmacology, 35,764–774.PubMedCrossRef Bhattacharyya, S., Morrison, P.D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O’Carroll, C.M., Seal, M., Allen, P., Mehta, M.A., Stone, J.M., Tunstall, N., Giampietro, V., Kapur, S., Murray, R.M., Zuardi, A.W., Crippa, J.A., Atakan, Z., & McGuire, P.K. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.Neuropsychopharmacology, 35,764–774.PubMedCrossRef
go back to reference Bisogno, T., Hanus, L., DePetrocellis, L., Tchilibon, S., Ponde, D.E., Brandi, I., Moriello, A.S., Davis, J.B., Mechoulam, R., & Di Marzo, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.British Journal of Pharmacology, 134,845–852.PubMedCrossRef Bisogno, T., Hanus, L., DePetrocellis, L., Tchilibon, S., Ponde, D.E., Brandi, I., Moriello, A.S., Davis, J.B., Mechoulam, R., & Di Marzo, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.British Journal of Pharmacology, 134,845–852.PubMedCrossRef
go back to reference Campos, A.C., & Guimaraes, F.S. (2008). Involvement of 5HT1A receptors in the anxiolytic- like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats.Psychopharmacology (Berl), 199,223–230.CrossRef Campos, A.C., & Guimaraes, F.S. (2008). Involvement of 5HT1A receptors in the anxiolytic- like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats.Psychopharmacology (Berl), 199,223–230.CrossRef
go back to reference Caspi, A., Moffitt, T.E., Cannon, M., McClay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., Poulton, R., & Craig, I.W. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction.Biological Psychiatry, 57,1117–1127.PubMedCrossRef Caspi, A., Moffitt, T.E., Cannon, M., McClay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., Poulton, R., & Craig, I.W. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction.Biological Psychiatry, 57,1117–1127.PubMedCrossRef
go back to reference Crippa, J.A., Zuardi, A.W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar-Poli, P. (2009). Cannabis and anxiety: a critical review of the evidence.Human Psychopharmacology, 24,515–523.PubMedCrossRef Crippa, J.A., Zuardi, A.W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar-Poli, P. (2009). Cannabis and anxiety: a critical review of the evidence.Human Psychopharmacology, 24,515–523.PubMedCrossRef
go back to reference D’Souza, D.C. (2007). Cannabinoids and psychosis.International Reviews in Neurobiology, 78,289–326.CrossRef D’Souza, D.C. (2007). Cannabinoids and psychosis.International Reviews in Neurobiology, 78,289–326.CrossRef
go back to reference D’Souza, D.C., Sewell, R.A., & Ranganathan, M. (2009). Cannabis and psychosis/ schizophrenia: human studies.European Archives of Psychiatry and Clinical Neuroscience, 259,413–431.PubMedCrossRef D’Souza, D.C., Sewell, R.A., & Ranganathan, M. (2009). Cannabis and psychosis/ schizophrenia: human studies.European Archives of Psychiatry and Clinical Neuroscience, 259,413–431.PubMedCrossRef
go back to reference De Petrocellis, L., & Di Marzo., V. (2010). Non-CB1, non-CB2-receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.Journal of Neuroimmune Pharmacology, 5,103–121.PubMedCrossRef De Petrocellis, L., & Di Marzo., V. (2010). Non-CB1, non-CB2-receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.Journal of Neuroimmune Pharmacology, 5,103–121.PubMedCrossRef
go back to reference Degenhardt, L., Roxburgh, A., & McKetin, R. (2007). Hospital separations for cannabis- and methamphetamine-related psychotic episodes in Australia.Medical Journal of Australia, 186,342–345.PubMed Degenhardt, L., Roxburgh, A., & McKetin, R. (2007). Hospital separations for cannabis- and methamphetamine-related psychotic episodes in Australia.Medical Journal of Australia, 186,342–345.PubMed
go back to reference Demirakca, T., Sartorius, A., Ende, G., Meyer, N., Welzel, H., Skopp, G., Mann, K., & Hermann, D. (2011). Diminished gray matter in the hippocampus of cannabis users: Possible protective effects of cannabidiol.Drug and Alcohol Dependence, 114,242–245.PubMed Demirakca, T., Sartorius, A., Ende, G., Meyer, N., Welzel, H., Skopp, G., Mann, K., & Hermann, D. (2011). Diminished gray matter in the hippocampus of cannabis users: Possible protective effects of cannabidiol.Drug and Alcohol Dependence, 114,242–245.PubMed
go back to reference Di Forti M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T.R., Handley, R., Luzi, S., Russo, M., Paparelli, A., Butt, A., Stilo, S.A., Wiffen, B., Powell, J., & Murray, R.M. (2009). High-potency cannabis and the risk of psychosis.British Journal of Psychiatry, 195,488–491.PubMedCrossRef Di Forti M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T.R., Handley, R., Luzi, S., Russo, M., Paparelli, A., Butt, A., Stilo, S.A., Wiffen, B., Powell, J., & Murray, R.M. (2009). High-potency cannabis and the risk of psychosis.British Journal of Psychiatry, 195,488–491.PubMedCrossRef
go back to reference Dragt, S., Nieman, D.H., Schultze-Lutter, F., Meer, F. van der, Becker, H., Haan, L. de, Dingemans, P.M., Birchwood, M., Patterson, P., Salokangas, R.K., Heinimaa, M., Heinz, A., Juckel, G., Graf von Reventlow, H., French, P., Stevens, H., Ruhrmann, S., Klosterkotter, J., & Linszen, D.H. (2012). Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis.Acta Psychiatrica Scandinavia, 125,45–53.CrossRef Dragt, S., Nieman, D.H., Schultze-Lutter, F., Meer, F. van der, Becker, H., Haan, L. de, Dingemans, P.M., Birchwood, M., Patterson, P., Salokangas, R.K., Heinimaa, M., Heinz, A., Juckel, G., Graf von Reventlow, H., French, P., Stevens, H., Ruhrmann, S., Klosterkotter, J., & Linszen, D.H. (2012). Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis.Acta Psychiatrica Scandinavia, 125,45–53.CrossRef
go back to reference Field, M., Eastwood, B., Bradley, B.P., & Mogg, K. (2006). Selective processing of cannabis cues in regular cannabis users.Drug and Alcohol Dependence, 85,75–82.PubMedCrossRef Field, M., Eastwood, B., Bradley, B.P., & Mogg, K. (2006). Selective processing of cannabis cues in regular cannabis users.Drug and Alcohol Dependence, 85,75–82.PubMedCrossRef
go back to reference Fischedick, J., Kooij, F. van der, & Verpoorte, R. (2010). Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor.Chemical Pharmacological Bulletin (Tokyo), 58,201–207.CrossRef Fischedick, J., Kooij, F. van der, & Verpoorte, R. (2010). Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor.Chemical Pharmacological Bulletin (Tokyo), 58,201–207.CrossRef
go back to reference Gaoni, Y., & Mechoulam, R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society 86,1646–1647.CrossRef Gaoni, Y., & Mechoulam, R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society 86,1646–1647.CrossRef
go back to reference Grotenhermen, F. (2004). Pharmacology of cannabinoids.Neurology and Endocrinology Letters, 25,14–23. Grotenhermen, F. (2004). Pharmacology of cannabinoids.Neurology and Endocrinology Letters, 25,14–23.
go back to reference Hampson, A.J., Grimaldi, M., Lolic, M., Wink, D., Rosenthal, R., & Axelrod, J. (2000). Neuroprotective antioxidants from marijuana.Annual of the New York Academy of Science, 899,274–282.CrossRef Hampson, A.J., Grimaldi, M., Lolic, M., Wink, D., Rosenthal, R., & Axelrod, J. (2000). Neuroprotective antioxidants from marijuana.Annual of the New York Academy of Science, 899,274–282.CrossRef
go back to reference Harvey, B.S., Ohlsson, K.S., Maag, J.L., Musgrave, I.F., & Smid, S.D. (2012). Contrasting protective effects of cannabinoids against oxidative stress and amyloidbeta evoked neurotoxicity in vitro.Neurotoxicology, 33,138–146.PubMedCrossRef Harvey, B.S., Ohlsson, K.S., Maag, J.L., Musgrave, I.F., & Smid, S.D. (2012). Contrasting protective effects of cannabinoids against oxidative stress and amyloidbeta evoked neurotoxicity in vitro.Neurotoxicology, 33,138–146.PubMedCrossRef
go back to reference Harvey, D.J., Samara, E., & Mechoulam, R. (1991). Comparative metabolism of cannabidiol in dog, rat and man.Pharmacology Biochemistry and Behavior, 40,523–532.CrossRef Harvey, D.J., Samara, E., & Mechoulam, R. (1991). Comparative metabolism of cannabidiol in dog, rat and man.Pharmacology Biochemistry and Behavior, 40,523–532.CrossRef
go back to reference Howlett, A.C., Johnson, M.R., Melvin, L.S., & Milne, G.M. (1988). Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model.Molecular Pharmacology, 33,297–302.PubMed Howlett, A.C., Johnson, M.R., Melvin, L.S., & Milne, G.M. (1988). Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model.Molecular Pharmacology, 33,297–302.PubMed
go back to reference Hunault, C.C., Mensinga, T.T., Bocker, K.B., Schipper, C.M., Kruidenier, M., Leenders, M.E., Vries, I. de, & Meulenbelt, J. (2009). Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).Psychopharmacology (Berl), 204,85–94.CrossRef Hunault, C.C., Mensinga, T.T., Bocker, K.B., Schipper, C.M., Kruidenier, M., Leenders, M.E., Vries, I. de, & Meulenbelt, J. (2009). Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).Psychopharmacology (Berl), 204,85–94.CrossRef
go back to reference Karschner, E.L., Darwin, W.D., McMahon, R.P., Liu, F., Wright, S., Goodwin, R.S., & Huestis, M.A. (2011). Subjective and physiological effects after controlled Sativex and oral THC administration.Clinical Pharmacology and Therapeutics, 89,400–407.PubMedCrossRef Karschner, E.L., Darwin, W.D., McMahon, R.P., Liu, F., Wright, S., Goodwin, R.S., & Huestis, M.A. (2011). Subjective and physiological effects after controlled Sativex and oral THC administration.Clinical Pharmacology and Therapeutics, 89,400–407.PubMedCrossRef
go back to reference Large, M., Sharma, S., Compton, M.T., Slade, T., & Nielssen, O. (2011). Cannabis use and earlier onset of psychosis: a systematic meta-analysis.Archives of General Psychiatry, 68,555–561.PubMedCrossRef Large, M., Sharma, S., Compton, M.T., Slade, T., & Nielssen, O. (2011). Cannabis use and earlier onset of psychosis: a systematic meta-analysis.Archives of General Psychiatry, 68,555–561.PubMedCrossRef
go back to reference Lastres-Becker, I., Molina-Holgado, F., Ramos, J.A., Mechoulam, R., & Fernandez-Ruiz, J. (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease.Neurobiological Diseases, 19,96–107.CrossRef Lastres-Becker, I., Molina-Holgado, F., Ramos, J.A., Mechoulam, R., & Fernandez-Ruiz, J. (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease.Neurobiological Diseases, 19,96–107.CrossRef
go back to reference Ligresti, A., Cascio, M.G., Pryce, G., Kulasegram, S., Beletskaya, I., DePetrocellis, L., Saha, B., Mahadevan, A., Visintin, C., Wiley, J.L., Baker, D., Martin, B.R., Razdan, R.K., & Di Marzo, V. (2006). New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis.British Journal of Pharmacology, 147,83–91.PubMedCrossRef Ligresti, A., Cascio, M.G., Pryce, G., Kulasegram, S., Beletskaya, I., DePetrocellis, L., Saha, B., Mahadevan, A., Visintin, C., Wiley, J.L., Baker, D., Martin, B.R., Razdan, R.K., & Di Marzo, V. (2006). New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis.British Journal of Pharmacology, 147,83–91.PubMedCrossRef
go back to reference Linszen, D.H., Dingemans, P.M., & Lenior, M.E. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders.Archives of General Psychiatry, 51,273–279.PubMedCrossRef Linszen, D.H., Dingemans, P.M., & Lenior, M.E. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders.Archives of General Psychiatry, 51,273–279.PubMedCrossRef
go back to reference Mechoulam, R., & Carlini, E.A. (1978). Toward drugs derived from cannabis.Naturwissenschaften, 65,174–179.PubMedCrossRef Mechoulam, R., & Carlini, E.A. (1978). Toward drugs derived from cannabis.Naturwissenschaften, 65,174–179.PubMedCrossRef
go back to reference Mechoulam, R., & Shvo, Y. (1963). The structure of cannabidiol.Tetrahedron 19, 2073-2078. Mechoulam, R., & Shvo, Y. (1963). The structure of cannabidiol.Tetrahedron 19, 2073-2078.
go back to reference Mercier, B., Prost, J., & Prost, M. (2009). The essential oil of turpentine and its major volatile fraction (alpha- and beta-pinenes): a review.International Journal of Occupational Medicine and Environmental Health, 22,331–342.PubMedCrossRef Mercier, B., Prost, J., & Prost, M. (2009). The essential oil of turpentine and its major volatile fraction (alpha- and beta-pinenes): a review.International Journal of Occupational Medicine and Environmental Health, 22,331–342.PubMedCrossRef
go back to reference Moreira, F.A., & Wotjak, C.T. (2010). Cannabinoids and anxiety.Current Topics in Behavioral Neuroscience, 2,429–450.CrossRef Moreira, F.A., & Wotjak, C.T. (2010). Cannabinoids and anxiety.Current Topics in Behavioral Neuroscience, 2,429–450.CrossRef
go back to reference Morgan, C.J., & Curran, H.V. (2008). Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis.British Journal of Psychiatry, 192,306–307.PubMedCrossRef Morgan, C.J., & Curran, H.V. (2008). Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis.British Journal of Psychiatry, 192,306–307.PubMedCrossRef
go back to reference Morgan, C.J., Freeman, T.P., Schafer, G.L., & Curran, H.V. (2010). Cannabidiol attenuates the appetitive effects of delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.Neuropsychopharmacology, 35,1879–1885.PubMedCrossRef Morgan, C.J., Freeman, T.P., Schafer, G.L., & Curran, H.V. (2010). Cannabidiol attenuates the appetitive effects of delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.Neuropsychopharmacology, 35,1879–1885.PubMedCrossRef
go back to reference Morgan, C.J., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T.P., Warrington, P., Rupasinghe, I., Ramoutar, A., Tan, N., Wingham, G., Lewis, S., & Curran, H.V. (2012). Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.Psychological Medicine,42,1–10.CrossRef Morgan, C.J., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T.P., Warrington, P., Rupasinghe, I., Ramoutar, A., Tan, N., Wingham, G., Lewis, S., & Curran, H.V. (2012). Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.Psychological Medicine,42,1–10.CrossRef
go back to reference Morgan, C.J., Schafer, G., Freeman, T.P., & Curran, H.V. (2009). Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected].British Journal of Psychiatry, 197,285–290.CrossRef Morgan, C.J., Schafer, G., Freeman, T.P., & Curran, H.V. (2009). Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected].British Journal of Psychiatry, 197,285–290.CrossRef
go back to reference Niesink, R.J.M., & Laar, M. van (2012).THC, CBD en gezondheidseffecten van wiet en hasj. Recente inzichten. Utrecht: Trimbos-instituut. Niesink, R.J.M., & Laar, M. van (2012).THC, CBD en gezondheidseffecten van wiet en hasj. Recente inzichten. Utrecht: Trimbos-instituut.
go back to reference Ramaekers, J.G., Berghaus, G., Laar, M. van, & Drummer, O.H. (2004). Dose related risk of motor vehicle crashes after cannabis use.Drug and Alcohol Dependence, 73,109–119.PubMedCrossRef Ramaekers, J.G., Berghaus, G., Laar, M. van, & Drummer, O.H. (2004). Dose related risk of motor vehicle crashes after cannabis use.Drug and Alcohol Dependence, 73,109–119.PubMedCrossRef
go back to reference Ranganathan, M., & D’Souza, D.C. (2006). The acute effects of cannabinoids on memory in humans: a review.Psychopharmacology (Berl), 188,425–444.CrossRef Ranganathan, M., & D’Souza, D.C. (2006). The acute effects of cannabinoids on memory in humans: a review.Psychopharmacology (Berl), 188,425–444.CrossRef
go back to reference Rigter, S., & Niesink, R. (2011).THC-concentraties in wiet, nederwiet en hasj in Nederlandse coffeeshops (2010-2011). Utrecht: Trimbos-instituut. Rigter, S., & Niesink, R. (2011).THC-concentraties in wiet, nederwiet en hasj in Nederlandse coffeeshops (2010-2011). Utrecht: Trimbos-instituut.
go back to reference Rosenthal, E. (2001).The big book of buds. Oakland, CA: Quick American Archives. Rosenthal, E. (2001).The big book of buds. Oakland, CA: Quick American Archives.
go back to reference Russo, E.B., Burnett, A., Hall, B., & Parker, K.K. (2005). Agonistic properties of cannabidiol at 5-HT1a receptors.Neurochemical Research, 30,1037–1043.PubMedCrossRef Russo, E.B., Burnett, A., Hall, B., & Parker, K.K. (2005). Agonistic properties of cannabidiol at 5-HT1a receptors.Neurochemical Research, 30,1037–1043.PubMedCrossRef
go back to reference Schubart, C.D., Gastel, W.A. van, Breetvelt, E.J., Beetz, S.L., Ophoff, R.A., Sommer, I.E., Kahn, R.S., & Boks, M.P. (2010). Cannabis use at a young age is associated with psychotic experiences.Psychological Medicine,40,1–10.CrossRef Schubart, C.D., Gastel, W.A. van, Breetvelt, E.J., Beetz, S.L., Ophoff, R.A., Sommer, I.E., Kahn, R.S., & Boks, M.P. (2010). Cannabis use at a young age is associated with psychotic experiences.Psychological Medicine,40,1–10.CrossRef
go back to reference Scuderi, C., Filippis, D.D., Iuvone, T., Blasio, A., Steardo, A., & Esposito, G. (2009). Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders.Phytotherapy Research, 23,597–602.PubMedCrossRef Scuderi, C., Filippis, D.D., Iuvone, T., Blasio, A., Steardo, A., & Esposito, G. (2009). Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders.Phytotherapy Research, 23,597–602.PubMedCrossRef
go back to reference Wiers, R. (2009). Automatische en controleerbare processen en het ontstaan van verslaving. In I. Franken & W. van den Brink (Eds.),Handboek verslaving (pp.115–134). Utrecht: De Tijdstroom. Wiers, R. (2009). Automatische en controleerbare processen en het ontstaan van verslaving. In I. Franken & W. van den Brink (Eds.),Handboek verslaving (pp.115–134). Utrecht: De Tijdstroom.
go back to reference Winton-Brown, T.T., Allen, P., Bhattacharyya, S., Borgwardt, S.J., Fusar-Poli, P., Crippa, J.A., Seal, M.L., Martin-Santos, R., Ffytche, D., Zuardi, A.W., Atakan, Z., & McGuire, P.K. (2011). Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study.Neuropsychopharmacology, 36,1340–1348.PubMedCrossRef Winton-Brown, T.T., Allen, P., Bhattacharyya, S., Borgwardt, S.J., Fusar-Poli, P., Crippa, J.A., Seal, M.L., Martin-Santos, R., Ffytche, D., Zuardi, A.W., Atakan, Z., & McGuire, P.K. (2011). Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study.Neuropsychopharmacology, 36,1340–1348.PubMedCrossRef
go back to reference Zuardi, A.W. (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.Revista Brasileira de Psiquiatria, 30,271–280.PubMedCrossRef Zuardi, A.W. (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.Revista Brasileira de Psiquiatria, 30,271–280.PubMedCrossRef
go back to reference Zuardi, A.W., Guimaraes, F.S., & Moreira, A.C. (1993). Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers.Brazilian Journal of Medical Biological Research, 26,213–217. Zuardi, A.W., Guimaraes, F.S., & Moreira, A.C. (1993). Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers.Brazilian Journal of Medical Biological Research, 26,213–217.
go back to reference Zuardi, A.W., Shirakawa, I., Finkelfarb, E., & Karniol, I.G. (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.Psychopharmacology (Berl), 76,245–250.CrossRef Zuardi, A.W., Shirakawa, I., Finkelfarb, E., & Karniol, I.G. (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.Psychopharmacology (Berl), 76,245–250.CrossRef
go back to reference Zuurman, L., Roy, C., Schoemaker, R.C., Hazekamp, A., Hartigh, H.J. den, Bender, J.C., Verpoorte, R., Pinquier, J.L., Cohen, A.F., & Gerven, J.M. van (2008).Effect of intrapulmonary tetrahydrocannabinol administration in humans.Journal of Psychopharmacoly, 22,707–716.CrossRef Zuurman, L., Roy, C., Schoemaker, R.C., Hazekamp, A., Hartigh, H.J. den, Bender, J.C., Verpoorte, R., Pinquier, J.L., Cohen, A.F., & Gerven, J.M. van (2008).Effect of intrapulmonary tetrahydrocannabinol administration in humans.Journal of Psychopharmacoly, 22,707–716.CrossRef
Metagegevens
Titel
Cannabidiol: de nieuwe haarlemmerolie of een hype?
Auteurs
Dr. R. J. M. Niesink
Dr. M.W. van Laar
Publicatiedatum
01-06-2012
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Verslaving / Uitgave 2/2012
Print ISSN: 1574-1842
Elektronisch ISSN: 1875-7073
DOI
https://doi.org/10.1007/s12501-012-0020-5

Andere artikelen Uitgave 2/2012

Verslaving 2/2012 Naar de uitgave

OriginalPaper

Redactioneel

Verslaving verbeeld

Shame

Verslaving digitaal

NIDA-website